文献速递肿瘤 PET/CT

肽量对原发性前列腺癌患者68Ga-PSMA-11 PET/CT肿瘤摄取的影响:评估PSMA受体饱和

The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer.
PubMed 文献 · J Nucl Med · 2022-06-09

回顾性纳入362例原发性前列腺癌男性患者的68Ga-PSMA-11 PET/CT数据,按前列腺病灶体积四分位数分为3组,分析给药肽量与肿瘤摄取的相关性及肿瘤体积对参考器官摄取的影响。除第1组SUVmean与给药肽量呈显著正相关(P=0.008)外,各组的给药肽量与肿瘤摄取(SUVmean或SUVpeak)均无相关性。结论认为在约2.5 μg肽水平下,原发性前列腺癌患者未见明显受体饱和。

要点

  • 回顾性纳入362例原发性前列腺癌患者,按病灶体积四分位数分为3组。
  • 除第1组SUVmean与给药肽量显著正相关(P=0.008)外,各组给药肽量与肿瘤摄取无相关性。
  • 结论认为在约2.5 μg肽水平下,原发性前列腺癌患者未见明显受体饱和。

核心结论

  • 给药肽量对肿瘤68Ga-PSMA-11摄取无明显影响,仅第1组给药肽量与肿瘤SUVmean呈显著正相关。
  • 研究结果提示在约2.5 μg肽水平下,原发性前列腺癌男性患者未发生受体饱和。

研究设计与样本

  • 回顾性纳入362例原发性前列腺癌男性患者,均行68Ga-PSMA-11 PET/CT。
  • 对正常组织和原发肿瘤进行定量分析,按肿瘤体积四分位数将患者分为3组。
  • 采用相关分析和多变量线性回归分析。

主要发现

  • 中位索引病灶体积为9.50 cm3(范围0.064-174 cm3)。
  • 分组依据为前列腺病灶体积四分位数:≤4.11 cm3为第1组,4.11-20.6 cm3为第2组,≥20.6 cm3为第3组。
  • 除第1组SUVmean与给药肽量呈显著相关(P=0.008)外,各组给药肽量与肿瘤摄取(SUVmean或SUVpeak)均无相关性。
  • 线性回归分析支持上述发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-labeled prostate-specific membrane antigen (PSMA) is often produced on-site, where usually a fixed amount of peptide is conjugated to the generator eluate. However, fluctuations in specific activity might influence tracer distribution and tumor accumulation. Therefore, our aim was to investigate the potential effect of varying the administered peptide amount on 68Ga-PSMA-11 uptake in tumors using PET/CT in patients with primary prostate cancer (PCa). Additionally, the impact of tumor volume on this potential effect and on accumulation in reference organs was assessed. Methods: The imaging data of 362 men with primary PCa who underwent 68Ga-PSMA-11 PET/CT were retrospectively included. Scans were quantified for normal tissue and primary tumors. Patients were divided into 3 groups based on their tumor volume. Correlation and multivariable linear regression analyses were performed. Results: The median index lesion volume was 9.50 cm3 (range, 0.064-174 cm3). Groups were based on quartiles of prostatic lesion volume: ≤4.11 cm3 (group 1), 4.11-20.6 cm3 (group 2), and ≥20.6 cm3 (group 3). No correlation was found between administered peptide amount and tumor uptake (SUVmean or SUVpeak) for any group, except for a significant correlation for SUVmean in the first group (P = 0.008). Linear regression analysis supported these findings. Conclusion: The amount of administered peptide had no evident effect on 68Ga-PSMA-11 uptake in tumors, except for a significant positive correlation between administered peptide amount and tumor SUVmean for group 1. The findings imply that no receptor saturation occurs in men with primary PCa at peptide levels of about 2.5 μg.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Siebinga H, Heuvel JO, Rijkhorst EJ, et al. The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer. J Nucl Med. 2022. PMID: 35680416. doi:10.2967/jnumed.122.264101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。